43 research outputs found
Anomalous dimensions of leading twist conformal operators
We extend and develop a method for perturbative calculations of anomalous
dimensions and mixing matrices of leading twist conformal primary operators in
conformal field theories. Such operators lie on the unitarity bound and hence
are conserved (irreducible) in the free theory. The technique relies on the
known pattern of breaking of the irreducibility conditions in the interacting
theory. We relate the divergence of the conformal operators via the field
equations to their descendants involving an extra field and accompanied by an
extra power of the coupling constant. The ratio of the two-point functions of
descendants and of their primaries determines the anomalous dimension, allowing
us to gain an order of perturbation theory. We demonstrate the efficiency of
the formalism on the lowest-order analysis of anomalous dimensions and mixing
matrices which is required for two-loop calculations of the former. We compare
these results to another method based on anomalous conformal Ward identities
and constraints from the conformal algebra. It also permits to gain a
perturbative order in computations of mixing matrices. We show the complete
equivalence of both approaches.Comment: 21 pages, 4 figures; references adde
Operator mixing in N=4 SYM: The Konishi anomaly revisited
In the context of the superconformal N=4 SYM theory the Konishi anomaly can
be viewed as the descendant of the Konishi multiplet in the 10 of
SU(4), carrying the anomalous dimension of the multiplet. Another descendant
with the same quantum numbers, but this time without anomalous
dimension, is obtained from the protected half-BPS operator (the
stress-tensor multiplet). Both and are renormalized mixtures
of the same two bare operators, one trilinear (coming from the superpotential),
the other bilinear (the so-called "quantum Konishi anomaly"). Only the operator
is allowed to appear in the right-hand side of the Konishi anomaly
equation, the protected one does not match the conformal properties of
the left-hand side. Thus, in a superconformal renormalization scheme the
separation into "classical" and "quantum" anomaly terms is not possible, and
the question whether the Konishi anomaly is one-loop exact is out of context.
The same treatment applies to the operators of the BMN family, for which no
analogy with the traditional axial anomaly exists. We illustrate our abstract
analysis of this mixing problem by an explicit calculation of the mixing matrix
at level g^4 ("two loops") in the supersymmetric dimensional reduction scheme.Comment: 28 pp LaTeX, 3 figure
A three-loop test of the dilatation operator in N=4 SYM
We compute the three-loop anomalous dimension of the BMN operators with
charges J=0 (the Konishi multiplet) and J=1 in N=4 super-Yang-Mills theory. We
employ a method which effectively reduces the calculation to two loops. Instead
of using the superconformal primary states, we consider the ratio of the
two-point functions of suitable descendants of the corresponding multiplets.
Our results unambiguously select the form of the N=4 SYM dilatation operator
which is compatible with BMN scaling. Thus, we provide evidence for BMN scaling
at three loops.Comment: 38 pages LaTeX, 4 figures, references adde
On twist-two operators in N=4 SYM
We propose a mechanism for calculating anomalous dimensions of higher-spin
twist-two operators in N=4 SYM. We consider the ratio of the two-point
functions of the operators and of their superconformal descendants or,
alternatively, of the three-point functions of the operators and of the
descendants with two protected half-BPS operators. These ratios are
proportional to the anomalous dimension and can be evaluated at n-1 loop in
order to determine the anomalous dimension at n loops. We illustrate the method
by reproducing the well-known one-loop result by doing only tree-level
calculations. We work out the complete form of the first-generation descendants
of the twist-two operators and the scalar sector of the second-generation
descendants.Comment: references added; typos correcte
AvBD1 nucleotide polymorphisms, peptide antimicrobial activities and microbial colonisation of the broiler chicken gut
Abstract Background The importance of poultry as a global source of protein underpins the chicken genome and associated SNP data as key tools in selecting and breeding healthy robust birds with improved disease resistance. SNPs affecting host peptides involved in the innate defences tend to be rare, but three non-synonymous SNPs in the avian β-defensin (AvBD1) gene encoding the variant peptides NYH, SSY and NYY were identified that segregated specifically to three lines of commercial broiler chickens Line X (LX), Line Y(LY) and Line Z. The impacts of such amino acid changes on peptide antimicrobial properties were analysed in vitro and described in relation to the caecal microbiota and gut health of LX and LY birds. Results Time-kill and radial immune diffusion assays indicated all three peptides to have antimicrobial properties against gram negative and positive bacteria with a hierarchy of NYH > SSY > NYY. Calcein leakage assays supported AvBD1 NYH as the most potent membrane permeabilising agent although no significant differences in secondary structure were identified to explain this. However, distinct claw regions, identified by 3D modelling and proposed to play a key role in microbial membrane attachment, and permeation, were more distinct in the NYH model. In vivo AvBD1 synthesis was detected in the bird gut epithelia. Analyses of the caecal gut microbiota of young day 4 birds suggested trends in Lactobacilli sp. colonisation at days 4 (9% LX vs × 30% LY) and 28 (20% LX vs 12% LY) respectively, but these were not statistically significant (P > 0.05). Conclusion Amino acid changes altering the killing capacity of the AvBD1 peptide were associated with two different bird lines, but such changes did not impact significantly on caecal gut microbiota
AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i
RNA interference (RNAi) has been successfully employed for specific inhibition of gene expression; however, safety and delivery of RNAi remain critical issues. We investigated the combinatorial use of RNAi and U1 interference (U1i). U1i is a gene-silencing technique that acts on the pre-mRNA by preventing polyadenylation. RNAi and U1i have distinct mechanisms of action in different cellular compartments and their combined effect allows usage of minimal doses, thereby avoiding toxicity while retaining high target inhibition. As a proof of concept, we investigated knockdown of the firefly luciferase reporter gene by combinatorial use of RNAi and U1i, and evaluated their inhibitory potential both in vitro and in vivo. Co-transfection of RNAi and U1i constructs showed additive reduction of luciferase expression up to 95% in vitro. We attained similar knockdown when RNAi and U1i constructs were hydrodynamically transfected into murine liver, demonstrating for the first time successful in vivo application of U1i. Moreover, we demonstrated long-term gene silencing by AAV-mediated transduction of murine muscle with RNAi/U1i constructs targeting firefly luciferase. In conclusion, these results provide a proof of principle for the combinatorial use of RNAi and U1i to enhance target gene knockdown in vivo
RNAi for Treating Hepatitis B Viral Infection
Chronic hepatitis B virus (HBV) infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC). Current treatment strategies of HBV infection including the use of interferon (IFN)-α and nucleotide analogues such as lamivudine and adefovir have met with only partial success. Therefore, it is necessary to develop more effective antiviral therapies that can clear HBV infection with fewer side effects. RNA interference (RNAi), by which a small interfering RNA (siRNA) induces the gene silence at a post-transcriptional level, has the potential of treating HBV infection. The successful use of chemically synthesized siRNA, endogenous expression of small hairpin RNA (shRNA) or microRNA (miRNA) to silence the target gene make this technology towards a potentially rational therapeutics for HBV infection. However, several challenges including poor siRNA stability, inefficient cellular uptake, widespread biodistribution and non-specific effects need to be overcome. In this review, we discuss several strategies for improving the anti-HBV therapeutic efficacy of siRNAs, while avoiding their off-target effects and immunostimulation. There is an in-depth discussion on the (1) mechanisms of RNAi, (2) methods for siRNA/shRNA production, (3) barriers to RNAi-based therapies, and (4) delivery strategies of siRNA for treating HBV infection
Cerebrospinal fluid biomarker candidates associated with human WNV neuroinvasive disease
During the last decade, the epidemiology of WNV in humans has changed in the southern regions of Europe, with high incidence of West Nile fever (WNF) cases, but also of West Nile neuroinvasive disease (WNND). The lack of human vaccine or specific treatment against WNV infection imparts a pressing need to characterize indicators associated with neurological involvement. By its intimacy with central nervous system (CNS) structures, modifications in the cerebrospinal fluid (CSF) composition could accurately reflect CNS pathological process. Until now, few studies investigated the association between imbalance of CSF elements and severity of WNV infection. The aim of the present study was to apply the iTRAQ technology in order to identify the CSF proteins whose abundances are modified in patients with WNND. Forty-seven proteins were found modified in the CSF of WNND patients as compared to control groups, and most of them are reported for the first time in the context of WNND. On the basis of their known biological functions, several of these proteins were associated with inflammatory response. Among them, Defensin-1 alpha (DEFA1), a protein reported with anti-viral effects, presente
Erratum to: 36th International Symposium on Intensive Care and Emergency Medicine
[This corrects the article DOI: 10.1186/s13054-016-1208-6.]
Recommended from our members
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707